TLM

Talisman Metals PLC

Basic Resources First-pass screen £4.81m

130/1000 Overall fit

AI beneficiary 35% 5

Operating leverage 25% 10

Valuation 25% 30

Downside protection 15% 10

First-pass take

Biopharmaceutical company with zero AI exposure; lead asset Orenetide failed Phase II trial mid-2023. Pre-revenue, now in strategic review focused on minimizing losses. R&D-intensive model has no operating leverage.

Flags

not-aibiotech-failurepre-revenuestrategic-reviewno-valuation-data